ArticleSupportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer2022
3-T magnetic resonance-guided high-intensity focused ultrasound (3 T-MR-HIFU) for the treatment of pain from bone metastases of solid tumors.
Article in Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 20 citations in OpenAlex.
- Multimodal PET Defines a 'Goldilocks' Thermal Window for Focused Ultrasound Ablation and Immunotherapy Combinations.bioRxiv : the preprint server for biology · 2026Article
- Chinese expert consensus on magnetic resonance-guided focused ultrasound surgery for painful bone metastases.Insights into imaging · 2026Article
- Co-Ablation System for Pain Management in Bone Metastases: Retrospective Exploratory Study.JMIR cancer · 2026Article
- Non-Ossifying Fibromas: A 2025 Review.Journal of clinical medicine · 2025Review
- Focused Ultrasound for Sarcomas: A Narrative Review.Current oncology (Toronto, Ont.) · 2025Review
- Therapeutic Ultrasound for Multimodal Cancer Treatment: A Spotlight on Breast Cancer.Annual review of biomedical engineering · 2025Review
- Modern Treatment of Skeletal Metastases: Multidisciplinarity and the Concept of Oligometastasis in the Recent Literature.Current oncology (Toronto, Ont.) · 2025Review
- MR Imaging-Guided Focused Ultrasound for Breast Tumors.Magnetic resonance imaging clinics of North America · 2024Review
- Conversion in a Resectable Tumor after Denosumab Neoadjuvant in a Large Dorsal Giant Cells Tumor: A Case Report and a Literature Review.Current oncology (Toronto, Ont.) · 2023Review
- Managing spindle cell sarcoma with surgery and high-intensity focused ultrasound: A case report.World journal of clinical cases · 2023Article
- MR-guided ultrasound-stimulated microbubble therapy enhances radiation-induced tumor response.Scientific reports · 2023Article
- Current therapies and future prospective for locally aggressive mesenchymal tumors.Frontiers in oncology · 2023Review
- High Intensity Focused Ultrasound for Treatment of Bone Malignancies-20 Years of History.Cancers · 2022Review
- Minimally Invasive Interventional Procedures for Metastatic Bone Disease: A Comprehensive Review.Current oncology (Toronto, Ont.) · 2022Review
- Management of Long Bones Metastatic Disease: Concepts That We All Know but Not Always Remember.Orthopedic research and reviews · 2022Review
- Safety, tolerability, and pharmacokinetics/pharmacodynamics of JMT103 in patients with bone metastases from solid tumors.Frontiers in oncology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
20 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionBone metastases (BM) are still the main cause of morbidity and mortality in cancer patients, not only because of their complications, defined as skeletal-related events (SREs), but also because of the negative impact bone pain has on quality of life (QoL) and survival, especially when opioid analgesics and locoregional treatments fail. MATERIALS AND
methodsA single-center prospective study was carried out on 12 patients with symptomatic BM treated with MRI-guided focused ultrasound (MR-HIFU). The primary endpoint was the effectiveness of MR-HIFU in reducing current and breakthrough cancer pain (BTCP) scores. The main secondary aims were the evaluation of circulating markers at different time-points and their relation to pain and procedure efficacy. Other secondary objectives included temporal evolution of pain response, evaluation of QoL, and side effects of the treatment. Descriptive statistics were used to evaluate primary and secondary endpoints. Questionnaires on pain and QoL completed at baseline and at 30 days were compared using appropriate statistical tests with exploratory intent.
resultsMR-HIFU was successfully completed in all 12 patients enrolled between September 2015 and December 2018. On day 30, 6 (50.0%) patients showed a complete response of current pain and 6 a partial response, while 5 (41.7%) obtained a complete BTCP response. A partial response of BM evaluated by MD Anderson criteria was obtained in 9 (81.8%) patients. Only one patient progressed in the target lesion after MR-HIFU. No treatment-related adverse events were recorded. Bone turnover markers CTX/RANK-L (P) do not demonstrate any significant change with the pain or BM response.
conclusionIn our patients, targeted therapy of painful BM with MRI-guided focused ultrasound ablation was safe and showed encouraging early-onset and functional results.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.